• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Vaccine booster after Johnson & Johnson-Janssen priming are safe and immunogenic

byDavid XiangandHarsh Shah
March 23, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Both the Johnson & Johnson-Janssen (JJJ) and mRNA boosters provided an acceptable safety profile and immunogenic response in healthcare workers who received a primary JJJ vaccine.

2. After receiving a primary JJJ vaccine, patients had the strongest immunogenic response after receiving an mRNA booster.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The JJJ vaccine has been demonstrated to induce lower levels of Covid-19 spike protein-specific antibodies than the mRNA-based vaccines. Therefore, it has been proposed that mixing and matching Covid-19 vaccines enhances both the flexibility of vaccine administration and may induce broader immune responses. However, there is a gap in knowledge as to understanding the immunologic and safety assessments of the effect of mRNA boosters in persons who received a priming JJJ dose. This study found that boosting with mRNA vaccines provided the most efficient response in patients who received the single-shot JJJ dose as their primary vaccine. This study was limited by factors such as evaluating boosters in healthcare workers who are generally younger than participants in other studies of homologous vaccine regimens and their participants did not have severe coexisting conditions. Nevertheless, these study’s findings are significant, as they demonstrate that both homologous and heterologous booster regimens for those who received the JJJ primary dose provide an immunogenic response and increase vaccine effectiveness against infection and transmission of Covid-19.

Click to read the study in NEJM

Relevant Reading: Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina

In-Depth [randomized controlled trial]: This single-blind multicenter, randomized controlled trial involved healthcare workers who received a JJJ vaccine as their primary vaccination regimen. Patients were assigned to receive no booster, a Pfizer-BioNTech booster, a Moderna booster, or a JJJ booster. Healthcare workers who were between 18 and 75 years of age and did not have severe coexisting factors or conditions were eligible for the study. Patients who had receipt of treatment for cancer, use of immunosuppressant agents, solid-organ or bone marrow transplant, or a history of Covid-19 infection were excluded from the study. The primary outcome was the level of S-specific binding antibodies. Outcomes in the primary analysis were conducted via Mann-Whitney U tests to assess differences in log-transformed titer values. Based on the analysis, homologous or heterologous booster vaccination resulted in higher levels of S-specific binding antibodies, neutralizing antibodies, and T-cell responses compared to only receiving a single JJJ vaccine dose. Additionally, heterologous boosters had a significantly larger increase in binding antibodies than with the homologous JJJ booster. The Moderna booster was also found to be the most immunogenic and associated with higher reactogenicity than the Pfizer-BioNTech and JJJ vaccines. Overall, this study demonstrated that vaccine boosters after receiving the single dose JJJ vaccine, whether homologous or heterologous, confer immunogenicity and improve vaccine effectiveness against infection and transmission of Covid-19. This can further help guide global discussions on the use of boosters, the prime-boost interval target population, and the level of Covid-19 circulation.

RELATED REPORTS

Awake prone positioning does not seem to offer benefit in reducing endotracheal intubation for COVID-19-induced acute respiratory failure: COVI-PRONE trial

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: boosterCoronavirusCOVID-19COVID-19 VaccineSARS-CoV-2
Previous Post

Very low birth weight associated with brain volume differences in adulthood

Next Post

#VisualAbstract: Pertuzumab plus trastuzumab significantly improves survival in metastatic breast cancer

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Emergency

Awake prone positioning does not seem to offer benefit in reducing endotracheal intubation for COVID-19-induced acute respiratory failure: COVI-PRONE trial

May 16, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

BNT162b2 safe and efficacious in children 5 to 11 years of age

May 13, 2022
Next Post
#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas

#VisualAbstract: Pertuzumab plus trastuzumab significantly improves survival in metastatic breast cancer

Large proportion of late preterm infants and older admitted to the NICU

Neonatal hypoglycemia not significantly associated with lower educational achievement during childhood

Multiple variables related to physical activity levels in preschool children

Cardiosphere-derived cell therapy slows disease progression in Duchenne muscular dystrophy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.